Solomon Moshkevich sold $66k of NTRA
PRESIDENT, CLINICALDIAGNOSTICS at Natera, Inc.. 550 shares at an average of $120.44, traded Oct 21, 2024, filed Oct 23, 2024.
Score components
- +20RolePresident
- +8Trade size$66k at market
- 0Share of holdings soldSold 0.5% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +41.0%, 3m +44.9%, 6m +25.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-025598, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 21, 2024 | SOpen-market sale Common Stock10b5-1 | -294 | $120.76 | $36k | 112,147 | Oct 23, 2024 |
| Oct 22, 2024 | SOpen-market sale Common Stock10b5-1 | -256 | $120.07 | $31k | 111,891 | Oct 23, 2024 |
Related signals
Other insiders at Natera, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $526k 1,273 shares | -1% | |
| 40Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $1.2M 3,000 shares | -3% | |
| 55Moderate | Natera, Inc. | Jonathan Sheena director, other | $7.0M 18,064 shares | -100% | |
| 35Weak | Natera, Inc. | Jonathan Sheena director, other | $3.2M 9,150 shares | -4% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $35M 102,000 shares | -5% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $16M 50,000 shares | -2% | |
| 39Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $545k 1,698 shares | -2% | |
| 45Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $5.9M 18,160 shares | -14% | |
| 48Moderate | Natera, Inc. | Roelof Botha director | $18M 75,000 shares | -6% | |
| 33Weak | Natera, Inc. | Roy D. Baynes director | $2.8M 12,780 shares | -54% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.